“Poor Person’s Cocaine”:

Bupropion Insufflation Inducing Manic Symptoms and Its Abuse Potential in Dual Diagnosis Patients

Greg Noe, BS; Samantha Ongchuan Martin, MD; Kaushal Shah, MD, MPH; and Sahil Munjal, MD

Recent findings estimate the prevalence of attention-deficit/hyperactivity disorder (ADHD) in substance use disorder (SUD) to be as high as 23.1%. Many report the use of recreational stimulants to suppress ADHD symptoms in the self-medication hypothesis. Among prescribers, bupropion is considered a substance of low abuse potential, with some studies showing less abuse potential than caffeine. However, we present a case of a patient with recurrent mania in the context of bupropion misuse.

Case Report

A 30-year-old man with a history of schizoaffective disorder (bipolar type), stimulant use disorder, and reported ADHD (later confirmed to meet DSM-5-TR criteria) presented to the emergency department (ED) in December 2021 with mania after an acute overdose of 35 pills of bupropion. He also reported overuse of bupropion by snorting four 150-mg bupropion pills per day in addition to his 300 mg daily as prescribed, with a total daily bupropion use of 900 mg. He presented with pressured speech, tangential thought processes, and poor judgment. He was given 50 mg of activated charcoal per poison control recommendations, with an additional 25 mg given 3 hours later. His mania was stabilized with risperidone, and he was discharged with clonidine to mitigate reported ADHD symptoms.

Discussion

This case, to our knowledge, is the first ever reported of bupropion misuse via insufflation causing manic symptoms in a patient with schizoaffective disorder. We conducted a systematic literature search in PubMed, PubMed Central, APA PsycINFO, MEDLINE, Web of Science, and Google Scholar databases with the help of Medical Subject Headings (MeSH) term Bupropion in the context of Substance-Related Disorders and Drug Misuse. Our search yielded only 5 relevant case reports (Table 1), but none in patients with psychotic disorders. The bupropion misuse noted in the 5 relevant case reports resulted mainly in seizures, without psychosis, and was found in patients without a diagnosis of schizoaffective disorder. Bupropion causes inhibition of both norepinephrine and dopamine reuptake, increasing the synaptic concentrations of these neurotransmitters. Additionally, bupropion has demonstrated increased activity in key brain reward systems, including the nucleus accumbens, a brain region implicated in addiction development. Animal studies demonstrate an extensive first-pass metabolism effect with bupropion, with bioavailability of 5%-20%. Insufflation causes a more rapid rise in plasma concentrations, potentially causing euphoria. Since the pharmacokinetics of bupropion have been characterized only for oral administration, there may be a discrepancy in the results of preclinical studies that did not find abuse potential for oral bupropion. Given that it produces cocaine-like euphoria, there is potential street value and evidence of diversion in correctional facilities.

It is not fully known how the patient initially received the diagnosis of ADHD, at what age it occurred, or its impact or course in his life. However, he was suffering from homelessness and was unemployed. He endorsed ADHD symptoms each time he presented to the ED, along with inattentiveness on examination. The patient stated during hospitalization that he “needed to be on stimulants for ADHD,” as he had responded well to them in the past. He cited this as the reason he repeatedly sought out cocaine, amphetamine, and methamphetamine illicitly. Due to his stimulant use disorder history, his bupropion was refilled during prior ED visits due to less perceived misuse potential. Bupropion was discontinued after the patient’s index visit, when his misuse was discovered.

Table 1.

Existing Case Reports Detailing Bupropion Misuse Via Insufflation or Intravenous (IV) Injection and Mania Associated With Bupropion Misuse

<table>
<thead>
<tr>
<th>Case Report 1</th>
<th>Case Report 2</th>
<th>Case Report 3</th>
<th>Case Report 4</th>
<th>Case Report 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seizure and recreational insufflation of bupropion in an adolescent</td>
<td>Recreational bupropion insufflation in an adolescent</td>
<td>Seizure in an adult from recreational insufflation of bupropion</td>
<td>Chronic intravenous use of bupropion in an adult in the context of smoking cessation</td>
<td>Refractory mania in a patient initiated on bupropion treatment for smoking cessation</td>
</tr>
</tbody>
</table>

*None of these patients had psychotic disorder or met criteria for dual diagnosis.
As medications previously categorized as having low misuse potential begin to show concerning patterns of misuse, it may be warranted to reevaluate drug prescribing and monitoring practices. Some safeguards could be the addition of bupropion to a prescription drug monitoring program or hard stops in the electronic medical records when re-prescribing medications noted with adverse outcomes.

**Conclusion**

This case highlights the importance of increasing physician awareness about the potential for prescription bupropion misuse. In patients with reported ADHD and substance use disorder, a high suspicion index may be warranted for potential misuse of bupropion.

**References**